Aligos Therapeutics Inc
NASDAQ:ALGS
Cash Flow Statement
Cash Flow Statement
Aligos Therapeutics Inc
| Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||||||
| Net Income |
(73)
|
(106)
|
(109)
|
(116)
|
(125)
|
(125)
|
(128)
|
(136)
|
(126)
|
(112)
|
(96)
|
(83)
|
(82)
|
(82)
|
(88)
|
(100)
|
(76)
|
(77)
|
(131)
|
(53)
|
(74)
|
(86)
|
|
| Depreciation & Amortization |
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
2
|
2
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Stock-Based Compensation |
1
|
2
|
3
|
5
|
9
|
11
|
13
|
14
|
15
|
15
|
15
|
15
|
14
|
13
|
13
|
12
|
11
|
9
|
8
|
7
|
6
|
5
|
|
| Other Non-Cash Items |
1
|
14
|
15
|
18
|
21
|
12
|
14
|
15
|
16
|
16
|
16
|
16
|
15
|
15
|
17
|
30
|
(3)
|
(4)
|
54
|
(23)
|
5
|
8
|
|
| Cash Taxes Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Working Capital |
3
|
6
|
16
|
11
|
12
|
12
|
(5)
|
12
|
(1)
|
(7)
|
(2)
|
(16)
|
(5)
|
(8)
|
(10)
|
(11)
|
(8)
|
(5)
|
(5)
|
(3)
|
(6)
|
(2)
|
|
| Cash from Operating Activities |
(66)
N/A
|
(83)
-25%
|
(74)
+11%
|
(84)
-13%
|
(89)
-6%
|
(98)
-10%
|
(116)
-18%
|
(106)
+8%
|
(108)
-2%
|
(100)
+8%
|
(79)
+21%
|
(81)
-2%
|
(70)
+14%
|
(73)
-5%
|
(79)
-8%
|
(79)
0%
|
(85)
-7%
|
(85)
+0%
|
(81)
+5%
|
(79)
+2%
|
(75)
+5%
|
(79)
-6%
|
|
| Investing Cash Flow | |||||||||||||||||||||||
| Capital Expenditures |
(3)
|
(3)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Other Items |
(21)
|
6
|
35
|
68
|
62
|
35
|
4
|
(66)
|
(86)
|
(53)
|
(25)
|
55
|
89
|
57
|
45
|
(64)
|
(49)
|
(38)
|
(18)
|
26
|
(53)
|
(15)
|
|
| Cash from Investing Activities |
(24)
N/A
|
3
N/A
|
33
+1 022%
|
66
+102%
|
61
-8%
|
34
-44%
|
3
-91%
|
(67)
N/A
|
(87)
-30%
|
(54)
+37%
|
(26)
+52%
|
54
N/A
|
89
+65%
|
57
-36%
|
45
-21%
|
(64)
N/A
|
(49)
+24%
|
(38)
+21%
|
(18)
+52%
|
26
N/A
|
(53)
N/A
|
(16)
+70%
|
|
| Financing Cash Flow | |||||||||||||||||||||||
| Net Issuance of Common Stock |
85
|
85
|
197
|
197
|
197
|
276
|
80
|
80
|
79
|
1
|
0
|
0
|
1
|
1
|
88
|
88
|
88
|
88
|
0
|
102
|
102
|
102
|
|
| Net Issuance of Debt |
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
|
| Other |
0
|
(1)
|
(4)
|
(4)
|
(4)
|
(4)
|
(1)
|
0
|
(1)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
86
N/A
|
85
-1%
|
192
+127%
|
192
+0%
|
193
+0%
|
271
+41%
|
79
-71%
|
79
0%
|
79
0%
|
1
-99%
|
0
-73%
|
0
+13%
|
1
+183%
|
1
N/A
|
88
+17 219%
|
88
0%
|
88
0%
|
88
+0%
|
0
-100%
|
102
+28 665%
|
102
0%
|
102
0%
|
|
| Change in Cash | |||||||||||||||||||||||
| Net Change in Cash |
(5)
N/A
|
4
N/A
|
151
+3 260%
|
175
+16%
|
165
-6%
|
208
+26%
|
(34)
N/A
|
(95)
-179%
|
(117)
-23%
|
(154)
-32%
|
(106)
+31%
|
(27)
+74%
|
20
N/A
|
(16)
N/A
|
54
N/A
|
(55)
N/A
|
(46)
+16%
|
(35)
+23%
|
(99)
-181%
|
50
N/A
|
(26)
N/A
|
7
N/A
|
|
| Free Cash Flow | |||||||||||||||||||||||
| Free Cash Flow |
(69)
N/A
|
(86)
-24%
|
(76)
+12%
|
(85)
-11%
|
(90)
-6%
|
(98)
-10%
|
(117)
-18%
|
(107)
+8%
|
(110)
-2%
|
(101)
+8%
|
(80)
+21%
|
(82)
-2%
|
(70)
+15%
|
(73)
-5%
|
(79)
-8%
|
(79)
-1%
|
(85)
-7%
|
(85)
+0%
|
(81)
+5%
|
(79)
+2%
|
(75)
+5%
|
(80)
-6%
|
|